Amberstone Biosciences snags $12m Series A

Amberstone Biosciences, an emerging biotherapeutics company, has closed $12 million in Series A financing.

Amberstone Biosciences, an emerging biotherapeutics company, has closed $12 million in Series A financing. Viva BioInnovator, Co-win Ventures and Sinovation Ventures led the round.

Source: Press Release